MASON, Ohio and TAMPA, Fla.—West Point Optical Group, LLC, providing quality patient care by developing experienced vision health teams within its 86 Pearle Vision stores, and Verséa Ophthalmics, Inc., a company focused on providing complete ocular point-of-care diagnostic and therapeutic interventions, have announced that the companies have entered into a partnership supply agreement in which Verséa Ophthalmics will be the exclusive provider of its Biovance and Biovance 3L ocular products, the only human amniotic membrane tissue products used within WPOG practices to support the treatment of ocular surface disease and ocular surgical applications.

Biovance and Biovance 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. Biovance 3L Ocular is acellular and consists of three layers of amniotic basement membrane that supports treatment of advanced ocular surface disease.

As a barrier membrane, Biovance 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction and other procedures, many of which are relevant to WPOG practices and their eyecare professional teams.

“We are excited to partner with Verséa Ophthalmics allowing our eyecare professionals to deliver the benefits of Biovance and Biovance 3L Ocular products to their patients,” said John Womack, OD, West Point Optical Group’s chief medical officer. “Verséa Ophthalmics has already been a wonderful partner to WPOG and this supply agreement only solidifies that partnership with amniotic membrane graft options that we believe are the best option for our patients.”

“As a corneal specialist by training, I have witnessed how innovative tissue-based ocular therapeutic interventions can drive forward innovation for ocular surface diseases,” said Rob Sambursky, MD, president, Verséa Ophthalmics, Inc. “Our exclusive partnership supply agreement with WPOG allows us to deliver a decellularized, ringless, advanced wound healing option to more patients, driving forward innovation for the management of ocular surface diseases.”

Terms of the agreement were not disclosed.